Literature DB >> 27170757

HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.

François M Pujol1, Vibor Laketa2,3, Florian Schmidt2, Markus Mukenhirn2,4, Barbara Müller2, Steeve Boulant2,4, Dirk Grimm2, Oliver T Keppler5, Oliver T Fackler6.   

Abstract

UNLABELLED: The host cell restriction factor CD317/tetherin traps virions at the surface of producer cells to prevent their release. The HIV-1 accessory protein Vpu antagonizes this restriction. Vpu reduces the cell surface density of the restriction factor and targets it for degradation; however, these activities are dispensable for enhancing particle release. Instead, Vpu has been suggested to antagonize CD317/tetherin by preventing recycling of internalized CD317/tetherin to the cell surface, blocking anterograde transport of newly synthesized CD317/tetherin, and/or displacing the restriction factor from virus assembly sites at the plasma membrane. At the molecular level, antagonism relies on the physical interaction of Vpu with CD317/tetherin. Recent findings suggested that phosphorylation of a diserine motif enables Vpu to bind to adaptor protein 1 (AP-1) trafficking complexes via two independent interaction motifs and to couple CD317/tetherin to the endocytic machinery. Here, we used a panel of Vpu proteins with specific mutations in individual interaction motifs to define which interactions are required for antagonism of CD317/tetherin. Impairing recycling or anterograde transport of CD317/tetherin to the plasma membrane was insufficient for antagonism. In contrast, excluding CD317/tetherin from HIV-1 assembly sites depended on Vpu motifs for interaction with AP-1 and CD317/tetherin and correlated with antagonism of the particle release restriction. Consistently, interference with AP-1 function or its expression blocked these Vpu activities. Our results define displacement from HIV-1 assembly sites as active principle of CD317/tetherin antagonism by Vpu and support a role of tripartite complexes between Vpu, AP-1, and CD317/tetherin in this process. IMPORTANCE: CD317/tetherin poses an intrinsic barrier to human immunodeficiency virus type 1 (HIV-1) replication in human cells by trapping virus particles at the surface of producer cells and thereby preventing their release. The viral protein Vpu antagonizes this restriction, and molecular interactions with the restriction factor and adaptor protein complex 1 (AP-1) were suggested to mediate this activity. Vpu modulates intracellular trafficking of CD317/tetherin and excludes the restriction factor from HIV-1 assembly sites at the plasma membrane, but the relative contribution of these effects to antagonism remain elusive. Using a panel of Vpu mutants, as well as interference with AP-1 function and expression, we show here that Vpu antagonizes CD317/tetherin by blocking its recruitment to viral assembly sites in an AP-1-dependent manner. These results refine our understanding of the molecular mechanisms of CD317/tetherin antagonism and suggest complexes of Vpu with the restriction factor and AP-1 as targets for potential therapeutic intervention.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27170757      PMCID: PMC4944280          DOI: 10.1128/JVI.00504-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

2.  HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.

Authors:  Joëlle V Fritz; Nadine Tibroni; Oliver T Keppler; Oliver T Fackler
Journal:  Virology       Date:  2012-01-04       Impact factor: 3.616

3.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

4.  HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.

Authors:  Heiko Hauser; Lisa A Lopez; Su Jung Yang; Jill E Oldenburg; Colin M Exline; John C Guatelli; Paula M Cannon
Journal:  Retrovirology       Date:  2010-06-07       Impact factor: 4.602

5.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.

Authors:  Christine Goffinet; Ina Allespach; Stefanie Homann; Hanna-Mari Tervo; Anja Habermann; Daniel Rupp; Lena Oberbremer; Christian Kern; Nadine Tibroni; Sonja Welsch; Jacomine Krijnse-Locker; George Banting; Hans-Georg Kräusslich; Oliver T Fackler; Oliver T Keppler
Journal:  Cell Host Microbe       Date:  2009-03-19       Impact factor: 21.023

6.  Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Johanne Mercier; Julie Binette; Grace Leung; Eric A Cohen
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

7.  The adaptor protein-1 μ1B subunit expands the repertoire of basolateral sorting signal recognition in epithelial cells.

Authors:  Xiaoli Guo; Rafael Mattera; Xuefeng Ren; Yu Chen; Claudio Retamal; Alfonso González; Juan S Bonifacino
Journal:  Dev Cell       Date:  2013-11-11       Impact factor: 12.270

8.  A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.

Authors:  Tonya Kueck; Stuart J D Neil
Journal:  PLoS Pathog       Date:  2012-03-29       Impact factor: 6.823

9.  Tetherin inhibits HIV-1 release by directly tethering virions to cells.

Authors:  David Perez-Caballero; Trinity Zang; Alaleh Ebrahimi; Matthew W McNatt; Devon A Gregory; Marc C Johnson; Paul D Bieniasz
Journal:  Cell       Date:  2009-10-30       Impact factor: 41.582

10.  Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum.

Authors:  Julie Binette; Mathieu Dubé; Johanne Mercier; Dalia Halawani; Martin Latterich; Eric A Cohen
Journal:  Retrovirology       Date:  2007-10-15       Impact factor: 4.602

View more
  15 in total

1.  Extracellular vesicles of the blood-brain barrier: Role in the HIV-1 associated amyloid beta pathology.

Authors:  Ibolya E András; Ana Leda; Marta Garcia Contreras; Luc Bertrand; Minseon Park; Marta Skowronska; Michal Toborek
Journal:  Mol Cell Neurosci       Date:  2016-12-29       Impact factor: 4.314

2.  Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains.

Authors:  Mariana G Bego; Lijun Cong; Katharina Mack; Frank Kirchhoff; Éric A Cohen
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

3.  The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.

Authors:  Shilpi Sharma; Moein Jafari; Amandip Bangar; Karen William; John Guatelli; Mary K Lewinski
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

4.  Substitutions in Nef That Uncouple Tetherin and SERINC5 Antagonism Impair Simian Immunodeficiency Virus Replication in Primary Rhesus Macaque Lymphocytes.

Authors:  Sanath Kumar Janaka; Brian J Snow; Ryan T Behrens; David T Evans
Journal:  J Virol       Date:  2022-05-10       Impact factor: 6.549

5.  Tetherin Antagonism by HIV-1 Group M Nef Proteins.

Authors:  Juan F Arias; Marta Colomer-Lluch; Benjamin von Bredow; Justin M Greene; Julie MacDonald; David H O'Connor; Ruth Serra-Moreno; David T Evans
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

6.  Intrinsic properties and plasma membrane trafficking route of Src family kinase SH4 domains sensitive to retargeting by HIV-1 Nef.

Authors:  Amanda J Chase; Rebecka Wombacher; Oliver T Fackler
Journal:  J Biol Chem       Date:  2018-03-27       Impact factor: 5.157

Review 7.  Hijacking of the Ubiquitin/Proteasome Pathway by the HIV Auxiliary Proteins.

Authors:  Tanja Seissler; Roland Marquet; Jean-Christophe Paillart
Journal:  Viruses       Date:  2017-10-31       Impact factor: 5.048

8.  Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism.

Authors:  Sabelo Lukhele; Éric A Cohen
Journal:  Retrovirology       Date:  2017-03-14       Impact factor: 4.602

Review 9.  Proteasomal Degradation Machinery: Favorite Target of HIV-1 Proteins.

Authors:  Sneh Lata; Ritu Mishra; Akhil C Banerjea
Journal:  Front Microbiol       Date:  2018-11-21       Impact factor: 5.640

10.  βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.

Authors:  Yul Eum Song; Daniel Cyburt; Tiffany M Lucas; Devon A Gregory; Terri D Lyddon; Marc C Johnson
Journal:  Viruses       Date:  2018-10-19       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.